In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …

Abstract 686 Background DLBCL has two molecular subtypes, termed activated B cell-like
(ABC) and germinal center B cell-like (GCB), with ABC DLBCL being less curable with …

The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B cell–like
(ABC) and germinal center B cell–like (GCB)—arise by distinct mechanisms, with ABC …

Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma are the most prevalent B-
lymphocyte neoplasms in which abnormal activation of the Bruton tyrosine kinase (BTK) …

Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed distinct
molecular subtypes that include germinal center B cell–like (GCB) and activated B cell–like …

PURPOSE Ibrutinib has shown activity in non–germinal center B-cell diffuse large B-cell
lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus …

Purpose: We have previously shown the prognostic significance of BCL2 expression in the
activated B-cell–like diffuse large B-cell lymphoma (ABC-DLBCL) patients treated with …

The importance of understanding the genetic and biochemical basis of B-cell receptor (BCR)
survival signaling in diffuse large B-cell lymphoma (DLBCL) is underscored by the recent …

Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …